Abivax skyrockets 400% as late-stage trial for lead asset succeeds in ulcerative colitis Abivax skyrockets 400% as late-stage trial for lead asset succeeds in ulcerative colitis Post ContentabvxRead More You might also be interested in reading UK retail sales drop more than expected in May. July 23, 2025 In Mainstream ← Previous post Next post →